Rona Therapeutics Completes $25M Pre-B Financing to Advance Nucleic Acid Drug Development
Rona Therapeutics
Nucleic Acid Drug Developer
Lilly Asia Ventures
Biopharmaceutical Investment Management Institution
BioTrack Capital
Healthcare Investment Institutions
▎WuXi AppTec Content Team Report
Today (March 14),Rona Therapeutics has just announced the completionPre-B Round Financing, with an Amount of Up to 25 Million US Dollars.This round of financingLed by Guanghua Phoenix, with the participation of both new and existing shareholders including Lilly Asia Ventures, Jiangyuan Investment, and BioTrack Capital.. This round of financing will help Rona Therapeutics advance its unique delivery and chemical modification platform technologies, further expanding its presence insiRNA Clinical Pipeline Layout in Cardiovascular Metabolism, Weight Loss, and Other Fieldsetc.
Rona Therapeutics was founded inIn 2021,Is a clinical-stage company in the field of nucleic acid drug research and development.The company is committed to solvingHypercholesterolemia, Hypertriglyceridemiaand other complex diseases.
Public information shows,The first pipeline of Rona Therapeutics isTargeting PCSK9(Subtype 9 of Proprotein Convertase)The new siRNA therapyRN0191. In November 2024, Rona Therapeutics presented positive Phase 1 trial results of RN0191 at the 2024 American Heart Association meeting: a single dose of RN0191 can achieve PCSK9 reduction.87% average maximum reduction and 95% individual maximum reduction; while achieving an average maximum reduction of 56% and an individual maximum reduction of 74% in LDL-C (low-density lipoprotein cholesterol). This lasting and stable therapeutic effect supportsAt least once every six monthsThe dosing regimen. The findings support the development of RN0191 as a monotherapy or in combination with other therapies to further reduce atherosclerotic cardiovascular risk.
RN0361, as the second pipeline project of Rona Therapeutics,TargetingAPOC3Double-stranded small interfering RNA (siRNA) drugsThe product has been approved for Phase 1 clinical trials in Australia, with proposed indications including (severe) hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial chylomicronemia syndrome.
[1]Rona Therapeutics Announces Completion of $25 Million Pre-B Round Financing to Accelerate Global Clinical Pipeline Expansion and Innovative Drug Development. Retrieved Mar 14, 2025 from https://mp.weixin.qq.com/s/6ORAhuZLOnEKdy3kkfd1ew
[3] Rona Therapeutics Announces Successful Approval of IND Application for RN0361, a Self-Developed APOC3 siRNA Drug, in Phase I Clinical Trial in Australia. Retrieved July 26, 2024, from https://mp.weixin.qq.com/s/-1retJudPC-EQrzoxZ13mg
[3] Rona Therapeutics Presented Positive Phase I Trial Results of Novel siRNA Therapy RN0191 Targeting PCSK9 at the 2024 American Heart Association. Retrieved Dec 18, 2024, from https://mp.weixin.qq.com/s/rGR3rVWcItvF_sUB4N5N6w
This article comes fromEdited and organized by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media circles. For authorization to repost or other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
